Sirt result, page-84

"Next Move for SIR Spheres In HCC
The data from SARAH can be marketed in Europe without restriction. This is likely to
assist in leading reimbursement reform, particularly in markets where there is currently no
reimbursement (France) or low levels of reimbursement (UK).
Treatment guidelines are also important. Professor Chris Verslype sits on the ESMO
Guidelines panel for the treatment of HCC. The Professor has contributed helpful
comments regarding efficacy and safety, hence it is probable that the ESMO guidelines for
treatment of the disease may be adjusted, particularly for later stage patients (i.e. BCLC
stage C).
The lead investigator (Professor Valerie Vilgrain) on the trial also concluded that, ‘liver
directed therapies with SIR spheres result in a significantly better tolerance of treatment
and quality of life. I believe this consideration should be a critical factor in selecting first​

line treatment for this patient population in the future’."

"

Next Milestones
The company will present the OS data from FOXFIRE (in mCRC) and SIRveNIB at ASCO
in early June.
Our Buy recommendation continues to assume a small survival benefit in the liver only
group of the mCRC studies.
We expect the results from the SIRveNIB trial in HCC to replicate the safety and efficacy​

data reported in SARAH."